CN1626545A - Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application - Google Patents
Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application Download PDFInfo
- Publication number
- CN1626545A CN1626545A CNA2004100591402A CN200410059140A CN1626545A CN 1626545 A CN1626545 A CN 1626545A CN A2004100591402 A CNA2004100591402 A CN A2004100591402A CN 200410059140 A CN200410059140 A CN 200410059140A CN 1626545 A CN1626545 A CN 1626545A
- Authority
- CN
- China
- Prior art keywords
- compound
- solvent
- shinyleaf yellowhorn
- handle
- xanthoceraside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 244000248162 Xanthoceras sorbifolium Species 0.000 title claims abstract description 38
- 235000009240 Xanthoceras sorbifolium Nutrition 0.000 title claims abstract description 38
- 238000000605 extraction Methods 0.000 title claims abstract description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 36
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000002904 solvent Substances 0.000 claims abstract description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 13
- 229930182490 saponin Natural products 0.000 claims abstract description 12
- 150000007949 saponins Chemical class 0.000 claims abstract description 12
- 238000010828 elution Methods 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 208000014644 Brain disease Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 239000011347 resin Substances 0.000 claims abstract description 7
- 229920005989 resin Polymers 0.000 claims abstract description 7
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 7
- 238000007670 refining Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 16
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- 235000017709 saponins Nutrition 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- 238000002386 leaching Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims 1
- 241000612118 Samolus valerandi Species 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 238000001704 evaporation Methods 0.000 abstract description 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 2
- 239000012141 concentrate Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000003480 eluent Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 229930182470 glycoside Natural products 0.000 abstract 1
- 150000002338 glycosides Chemical class 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000002023 wood Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 125000005601 angeloyl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930182493 triterpene saponin Natural products 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 241001632409 Aralia elata Species 0.000 description 1
- 235000015888 Aralia elata Nutrition 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000209507 Camellia Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DREXRFWZUBSPBF-UHFFFAOYSA-N N#CN.[S] Chemical compound N#CN.[S] DREXRFWZUBSPBF-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000408907 Xanthoceras Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229930193445 elatoside Natural products 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a xanthoceras sorbifolia bunge development and utilization technology, in particular to a compound extracted from xanthoceras sorbifolia shells and stems, an extraction method and application thereof, wherein the compound is named as xanthoceras sorbifolia bunge nutshell glycoside, and the chemical structural formula of the compound is as follows: the extraction method comprises the following steps: crushing xanthoceras sorbifolia shells and/or stems, extracting with a solvent, filtering, recovering the solvent to obtain a concentrated solution, passing the concentrated solution through macroporous resin, eluting with the solvent, recovering the solvent to obtain a concentrate, evaporating to dryness to obtain a brown solid, namely total saponin, dissolving the total saponin with water, extracting with n-butanol, drying to obtain brown powder, performing silica gel column chromatography, performing gradient elution with chloroform/methanol at a ratio of 100: 35-60, recovering an eluent, and refining to obtain a target compound xanthoceras sorbifolia bunge; the compound can be used for preparing medicines for treating brain diseases and tumors and health foods for preventing and treating brain diseases and tumors.
Description
Technical field
The present invention relates to the Wood of Shinyleaf Yellowhorn evaluation and exploration technology, is a kind of compound that extracts from shinyleaf yellowhorn shell and handle and extracting method and application specifically.
Background technology
Wood of Shinyleaf Yellowhorn (Xanthoceras Sobifolia) belongs to for the Sapindaceae Wood of Shinyleaf Yellowhorn, be the peculiar woody oleiferous plants plant of China, one genus is a kind of, mainly be distributed in China Liaoning, the Inner Mongol and Hexi Corridor one band, because of characteristics such as it have drought resisting, cold-resistant, barren-resistant, salt tolerant alkali, few, the easy breeding of disease and pest, solid morning, output is big, the life-span is long and check winds and fix drifting sand, surplus the whole nation has cultivated 70 at present ten thousand mu.
Wood of Shinyleaf Yellowhorn kind benevolence oil-containing 60% contains 14 kinds of unsaturated fatty acidss in the oil, can make edible oil.Wood of Shinyleaf Yellowhorn kind benevolence is edible, and it is sweet to distinguish the flavor of, and can control bed-wetting.
Yet up to now, shinyleaf yellowhorn fruit shell and carpopodium are not developed as yet and utilize for discarded thing.
Summary of the invention
The object of the present invention is to provide a kind of compound that from shinyleaf yellowhorn fruit shell and carpopodium, extracts and extracting method and application, adopt the present invention not only can make depleted shinyleaf yellowhorn fruit shell and carpopodium obtain development and use, turn waste into wealth, and in field of medicaments, will develop a kind of treatment disease of brain and antineoplastic new drug.
The objective of the invention is to be achieved through the following technical solutions:
A kind of compound that extracts from shinyleaf yellowhorn fruit shell and carpopodium, this compound are named to Xanthoceraside (Xanthoceraside), are triterpene saponin componds, and its chemical structure is:
3-O-(α-L-arabinofuranosyl (1 → 3)-β-D-galactopyranosyl (1 → 2))-β-D-glucuronopyranosyl-21,22-diangeloyl-R
1-barrigenol, i.e. 3-O-(α-L-arabinofuranosyl (1 → 3)-β-D-galactopyranose base (1 → 2))-beta d glucopyranosiduronic acid base-21,22-two angeloyl groups-R
1-barrigenol.
This compound is white needle, and molten point is 267-268 ℃, is the light red blackening under the 254nm wavelength, and the sulfuric acid colour developing is purple, and the Molish reaction is positive.
Its extracting method is: shinyleaf yellowhorn fruit shell and/or carpopodium are pulverized, used the solvent lixiviate, filter, reclaim solvent and get concentrated solution, concentrated solution is crossed macroporous resin, uses solvent elution, with active constituent-enriched, removes impurity, reclaim solvent and get enriched material, evaporate to dryness obtains brown solid, i.e. total saponins; With the total saponins water dissolution, use n-butanol extraction, dry brown powder through silica gel column chromatography repeatedly, is carried out gradient elution with chloroform/methanol=100: 35～60, reclaims elutriant, and is refining, obtains white needle, is purpose compound Xanthoceraside;
Described solvent is water, methyl alcohol, ethanol, propyl alcohol, butanols and/or acetone, and the concentration expressed in percentage by volume of solvent methanol, ethanol, propyl alcohol, butanols or acetone is 35%～85%;
In the described solvent leaching process, adopt at interval and stir, promptly every 10～20 minutes, stirred 1～5 minute, extraction temperature is 60～100 ℃, extraction time 1～3 hour.
Application of compound: be used for preparation treatment disease of brain and the medicine of tumour (solid tumor) and the functional health care food of prevention, treatment disease of brain and tumour.
The present invention has following advantage:
The present invention extracts a kind of brand-new compound from depleted shinyleaf yellowhorn fruit shell and carpopodium, through CA-CS (chemical substance index) and SCIFINDER retrieval, this compound does not appear in the newspapers, for triterpene saponin componds has increased a newcomer; The experimentation on animals of this compound shows: it has the brain function of raising and promptly promotes to remember, alleviate cerebral ischemia and anoxybiotic effect, and the cancer cell in vitro experiment of this compound shows: it has the effect that suppresses cancer cell in vitro; Thereby, the present invention has not only improved the biological value of exploiting and utilizing of depleted shinyleaf yellowhorn fruit shell and carpopodium greatly, the natural resources of saves valuable, and be expected in field of medicaments from now on, develop a kind of treatment disease of brain and anti-tumor drug and functional health care product thereof, its application prospect is very wide.
Description of drawings
Fig. 1 extracts the process flow sheet of new compound from shinyleaf yellowhorn shell and handle for the present invention.
Fig. 2 is Xanthoceraside ultraviolet spectrogram of the present invention (wavelength is 211.6nm, and its optical density is 0.4554, and peak heights is 0.1920).
Fig. 3 is Xanthoceraside hydrogen spectrogram (BMU-500-of the present invention
1H, δ are 0～12ppm (chemical shift)).
Fig. 4 is one of Xanthoceraside hydrogen spectrum enlarged view of the present invention (BMU-500-
1H, δ are 3.0～7.0ppm (chemical shift)).
Fig. 5 is two (BMU-500-of Xanthoceraside hydrogen spectrum enlarged view of the present invention
1H, δ are 0.4～2.4ppm (chemical shift)).
Fig. 6 is Xanthoceraside carbon spectrogram (BMU-500-of the present invention
13C, δ are 10～180ppm (chemical shift)).
Fig. 7 is one of Xanthoceraside carbon spectrum enlarged view of the present invention (BMU-500-
13C, δ are 10～50ppm (chemical shift)).
Fig. 8 is two (BMU-500-of Xanthoceraside carbon spectrum enlarged view of the present invention
13C, δ are 51～94ppm (chemical shift)).
Fig. 9 is three (BMU-500-of Xanthoceraside carbon spectrum enlarged view of the present invention
13C, δ are 100～155ppm (chemical shift)).
Figure 10 for the relevant collection of illustrative plates of Xanthoceraside carbon-hydrogen of the present invention (ARX-300,
1H-: δ is 0～10ppm,
13C-: δ is 0～180ppm).
Figure 11 amplify for Xanthoceraside carbon-hydrogen of the present invention is relevant one of collection of illustrative plates (ARX-300,
1H-: δ is 0.7～2.3ppm,
13C-: δ is 10～40ppm).
Figure 12 amplify for Xanthoceraside carbon-hydrogen of the present invention is relevant collection of illustrative plates two (ARX-300,
1H-: δ is 0.2～3.4ppm,
13C-: δ is 5～60ppm).
Figure 13 amplify for Xanthoceraside carbon-hydrogen of the present invention is relevant collection of illustrative plates three (ARX-300,
1H-: δ is 3～7ppm,
13C-: δ is 60～140ppm).
Figure 14 be the long-range relevant collection of illustrative plates of Xanthoceraside carbon-hydrogen of the present invention (BMU-500,
1H-:F
2Be 0.6～9ppm,
13C-:F
1Be 10～180ppm).
Figure 15 for one of long-range relevant amplification collection of illustrative plates of Xanthoceraside carbon-hydrogen of the present invention (BMU-500,
1H-:F
2Be 0.8～5.1ppm,
13C-:F
1Be 100～180ppm).
Figure 16 for the long-range relevant amplification collection of illustrative plates of Xanthoceraside carbon-hydrogen of the present invention two (BMU-500,
1H-:F
2Be 0.54～2ppm,
13C-:F
1Be 15～90ppm).
Figure 17 for the long-range relevant amplification collection of illustrative plates of Xanthoceraside carbon-hydrogen of the present invention three (BMU-500,
1H-:F
2Be 2.8～6.8ppm,
13C-:F
1Be 10～94ppm).
Figure 18 for the long-range relevant amplification collection of illustrative plates of Xanthoceraside carbon-hydrogen of the present invention four (BMU-500,
1H-:F
2Be 3.4～6.4ppm,
13C-:F
1Be 10～94ppm).
(ARX-300, δ are 0～10ppm) to Figure 19 for the relevant collection of illustrative plates of Xanthoceraside hydrogen-hydrogen of the present invention.
(ARX-300, δ 0.5～7ppm) for the relevant collection of illustrative plates of Xanthoceraside hydrogen-hydrogen of the present invention for Figure 20.
Figure 21-1 is an Xanthoceraside one-level mass spectrum of the present invention (MS).
Figure 21-2 is Xanthoceraside second order ms figure of the present invention (MS).
Embodiment
As shown in Figure 1, it is 30 orders that the 2000g shinyleaf yellowhorn fruit shell is crushed to granularity, is the ethanol lixiviate of 35% (V/V) with the concentration of 10 times of shell volumes, extraction temperature is 60 ℃, and extraction time is 3 hours, stirs 1 minute every 10 minutes in the leaching process, filter then, reclaim ethanol and get concentrated solution, concentrated solution is crossed 101 macroporous resins, use 35% ethanol elution,, remove impurity with active constituent-enriched, reclaim ethanol and get enriched material, evaporate to dryness obtains brown solid, i.e. total saponins; With the total saponins water dissolution, use n-butanol extraction, reclaim propyl carbinol, the dry brown powder that gets, through silica gel column chromatography repeatedly, carry out gradient elution with chloroform/methanol=100: 35～60, reclaim elutriant, recrystallization obtains the white needle of about 50mg, is purpose compound Xanthoceraside.
Get the purpose compound Xanthoceraside of said extracted, do experimentation on animals.
20 of mouse, the male and female dual-purpose, body weight 18-23g divides two groups, the administration group is irritated stomach and is given Xanthoceraside by the dosage of mouse body weight 9mg/kg, and control group is irritated the physiological saline that stomach waits capacity, after the administration 40 minutes, two groups of mouse are put into Y type labyrinth respectively, experimentize.The study of record mouse reaches the number of times of continuous 10 these standards of correct response wrong reaction before, surpasses 30 persons in 30 times, and experimental result sees Table 1:
Table 1 Xanthoceraside has the experimental data table that promotes the learning and memory of little mouse effect
| Group | Number of animals (only) | Dosage (mg/kg) | Wrong reaction number of times x ± SD | ????P |
| Physiological saline | ????10 | Deng dosage | ????28.2±4.4 | ????- |
| Xanthoceraside | ????10 | ??9 | ????6.9±2.3 | ????＜0.01 |
By in the table as seen, Xanthoceraside group mouse wrong reaction times obviously is less than physiological saline group (P＜0.01), shows that Xanthoceraside has promotion learning and memory of little mouse effect.
As shown in Figure 1,2000g Wood of Shinyleaf Yellowhorn carpopodium being pulverized, is the propyl carbinol lixiviate of 85% (V/V) with the concentration of 8 times of carpopodium volumes, extraction temperature is 75 ℃, and extraction time is 1 hour, stirs 5 minutes every 20 minutes in the leaching process, filter then, reclaim propyl carbinol and get concentrated solution, concentrated solution is crossed 101 macroporous resins, with 85% propyl carbinol wash-out,, remove impurity with active constituent-enriched, reclaim propyl carbinol and get enriched material, the enriched material evaporate to dryness obtains brown solid, i.e. total saponins; With the total saponins water dissolution, use n-butanol extraction, reclaim propyl carbinol, the dry brown powder that gets, through silica gel column chromatography repeatedly, carry out gradient elution with chloroform/methanol=100: 35～60, reclaim elutriant, recrystallization obtains the white needle of about 45mg, is purpose compound Xanthoceraside.
Get the Xanthoceraside of said extracted, do experimentation on animals.
Press Y type labyrinth three arm random approachs training mouse, preliminary election reaches before continuous 10 correct responses wrong reaction and is less than 30 persons and is used for experiment, after the preliminary election mouse had a rest 24 hours, be divided into two groups at random, equal abdominal injection Scopolamine 2.0mg/kg, cause the mouse memory obstacle, after 15 minutes, the administration group is by the dosage of mouse body weight 6mg/kg, the abdominal injection Xanthoceraside, capacity physiological saline such as control group abdominal injection, after the administration 20 minutes, two groups of mouse are put into Y type labyrinth respectively experimentize, record reaches wrong reaction number of times before continuous 10 correct responses, experimental result sees Table 2: table 2 Xanthoceraside has Scopolamine induced mice dysmnesia and promotes the memory represents effect
The experimental data table
| Group | Number of animals (only) | Dosage (mg/kg) | Wrong reaction number of times x ± SD | ????P |
| Physiological saline | ????8 | Deng dosage | ??17.9±3.6 | ????- |
| Xanthoceraside | ????8 | ????6 | ??4.0±1.5 | ????＜0.01 |
Xanthoceraside has the effect of the memory represents of promotion to Scopolamine induced mice dysmnesia as can be seen from the table.
1000g shinyleaf yellowhorn fruit shell and 1000g carpopodium are pulverized, and are the ethanol lixiviate of 50% (V/V) with the concentration of 10 times of shells and carpopodium volume, and extraction temperature is 90 ℃, extraction time is 2 hours, stirs 3 minutes every 15 minutes in the leaching process, filters then, reclaim ethanol and get concentrated solution, concentrated solution is crossed 101 macroporous resins, uses 50% ethanol elution, with active constituent-enriched, remove impurity, reclaim ethanol and get enriched material, evaporate to dryness, obtain brown solid, i.e. total saponins; With the total saponins water dissolution, use n-butanol extraction, reclaim propyl carbinol, the dry brown powder that gets, through silica gel column chromatography repeatedly, carry out gradient elution with chloroform/methanol=100: 35～60, reclaim elutriant, recrystallization obtains the white needle of about 50mg, is purpose compound Xanthoceraside.
Get the Xanthoceraside of said extracted, do the static anoxic experiment of conventional airtight bottle, observe the influence of Xanthoceraside the death time.
Test in two batches: respectively establish control group and Xanthoceraside administration group, with three index evaluation death times.Oral Xanthoceraside, every day secondary, 2mg/ time, totally 6 days.
1. organize mean time to death (xt) entirely;
2. the super average death time (xp): with control group mean time to death (xc) is standard, calculates greater than death time (xp) of the part animal of xc and averages;
3. prolong the death time (xp-xc): the promptly super average death time (xp) deducts xc and averages.
Experimental result sees Table 3.
Table 3 Xanthoceraside is to the influence of small white mouse hypoxia death time
| Index | Control group | The administration group | P |
| First xt (min) xp (min) xp-xc (min) second batch xt (min) xp (min) xp-xc (min) | 34.3±8.89(30 ※) 41.42±4.48(14) 5.54±4.46(14) 25.38±4.24(40) 27.54±2.87(24) 2.64±2.87(24) | 41.84±15.35(30 ※) 56.51±14.59(17) 14.59±14.83(17) 3?1.55±6.68(41) 33.40±4.94(33) 8.40±4.94(33) | ＜0.025 ＜0.05 ＜0.05 ＜0.001 ＜0.001 ＜0.001 |
※Be number of animals
All there is tangible difference three death times of control group and two batches of experiments of administration group as can be seen from Table 3, and the death time of administration group is longer than control group, prove that Xanthoceraside has the animal of raising to the anoxybiotic tolerance.Brain is very responsive to anoxic, because at first involve brain during anoxic, Xanthoceraside has improved the anoxybiotic tolerance, thereby has prolonged the death time of small white mouse.
As shown in Figure 1, the 2000g shinyleaf yellowhorn fruit shell is pulverized, boiled lixiviate with the water of 15 times of shell volumes, extraction time is 3 hours, stirred 2 minutes every 10 minutes in the leaching process, filter then, filtrate is crossed 101 macroporous resins, the water wash-out, with active constituent-enriched, remove impurity, evaporation concentration, concentrated solution n-butanol extraction, reclaim propyl carbinol, dry brown powder through silica gel column chromatography repeatedly, is carried out gradient elution with chloroform/methanol=100: 35～60, reclaim elutriant, recrystallization obtains the white needle of about 40mg, is purpose compound Xanthoceraside.
In addition, extraction solvent of the present invention also can use methyl alcohol, propyl alcohol or acetone.
Get the Xanthoceraside that embodiment 3 extracts, do the tumor cell in vitro experiment, experimental technique and the results are shown in Table 4.
Table 4 Xanthoceraside is to the screening active ingredients result of external six types of tumour cells
| Sequence number | Test model | Dosage (ug/ml) | Observation index | The test effect | The result | ????IC 50????(ug/ml) |
| ??1 ??2 ??3 ??4 ??5 ??6 | Mtt assay (HL-60 human leukemias) srb assay (PC-3MIE8 human prostata cancer) SRB (BGC-823 people's cancer of the stomach) srb assay (MDA-MB-435-human breast carcinoma) srb assay (Bel-7402 people's liver cancer) srb assay (Hela human cervical carcinoma) | ????0.5 ????5.0 ????50.0 ????0.5 ????5.0 ????50.0 ????0.5 ????5.0 ????50.0 ????0.5 ????5.0 ????50.0 ????0.5 ????5.0 ????50.0 ????0.5 ????5.0 ????50.0 | Inhibiting rate (%) inhibiting rate (%) inhibiting rate (%) inhibiting rate (%) inhibiting rate (%) inhibiting rate (%) | ????9.34 ????17.68 ????56.90 ????-13.90 ????-7.63 ????92.03 ????-11.71 ????-5.92 ????92.45 ????-4.50 ????2.92 ????93.14 ????-9.78 ????-1.24 ????92.96 ????-12.72 ????-4.05 ????95.49 | ????+ ????+ ????+ ????+ ????+ ????+ | ????41.29 ????40.98 ????40.24 ????18.58 ????39.32 ????34.23 |
Annotate: MTT: tetramethyl-azo azoles salt (dyeing), SRB: sulphur cyanamide B (dyeing) IC
50The cell half-inhibition concentration.
As can be seen from the table: Xanthoceraside is remarkable to external six types of tumour cell restraining effect effects.From the IC that calculates
50(half-inhibition concentration) as can be seen, when the concentration of Xanthoceraside only is 18.58ug/ml, breast cancer cell promptly being had restraining effect, secondly is to cervical cancer, liver cancer, cancer of the stomach, prostate cancer and leukemia cell's inhibition effect, its half-inhibition concentration is respectively 34.23ug/ml, 39.32ug/ml, 40.24ug/ml, 40.98ug/ml, 41.92ug/ml.Hence one can see that, and Xanthoceraside promptly has the good restraining effect to solid tumor cell under lower concentration, through further investigation, can develop the new drug of treatment tumour.
To the embodiment of the invention 1,2,3 and the 4 purpose compounds that extract, applied chemistry method and spectroscopic analysis (comprising: UV, ID-NMR, 2D-DMR, EI-MS, ESI-MS etc.), carried out structure and identified and attribution data: according to its UV, ESI-MS,
1H-NMR,
13C-NMR, HMQC, HMBC, TOCSY spectrum data (seeing Figure of description 2～21 for details), and consult document [1] Chen YJ, Takeda T, Ogihara Y, et al.Studies on the constituents of Xanthocerassorbifolia Bunge.III.Minor prosapogenins from the fruits of Xanthocerassorbifolia Bunge.[J] .Chem.Pharm.Bull, 1985,33 (1): 127-134; [2] YoshikawaM, Harada E, Matsuda H, et a Elatosides A and B, potent inhibitors of ethanolabsorption in rats from the bark of Aralia elata Seem.:The structure-activityrelationships of oleanolic acid oligoglycosid[J] .Chem.Pharm.Bull.1993,41 (11): 2069-2071.[3] Yoshikawa M, Harada E, Murakami T, et al.Camelliasaponins B1, B2, C1 and C2, new type inhibitors of ethanol absorptionin rats from the seeds of Camellia j aponica L.[J] .Chem.Pharm.Bull.1994,42 (3): it is 3-O-(α-L-arabinofuranosyl (1 → 3)-β-D-galactopyranosyl (1 → 2))-β-D-glucuronopyranosyl-21 that 742-744. identifies this compound structure, 22-diangeloyl-R
1-barrigenol, i.e. 3-O-(α-L-arabinofuranosyl (1 → 3)-β-D-galactopyranose base (1 → 2))-beta d glucopyranosiduronic acid base-21,22-two angeloyl groups-R
1-barrigenol, its chemical structure is as follows:
The detailed data ownership of purpose structure that compound carries out being identified through chemical method and spectroscopic analysis sees Table 5:
Table 5 Xanthoceraside nuclear magnetic data ownership table
No????
13C?NMR???
1H?NMR???????????????????????No??????
13C?NMR??????
1H?NMR
Aglycone?moiety???????????????????????????????Sugar?moiety
3-O-glucuronopyranosyl?moiety
1?????39.7????????????????????????????????????1′?????105.2?????????4.89(1H，d，J＝10.2Hz)
2?????26.7????????????????????????????????????2′?????78.9
3?????89.9???????3.21(1H，m)??????????????????3′?????86.4
4?????39.0????????????????????????????????????4′?????71.7
5?????55.7????????????????????????????????????5′?????77.3
6?????18.9????????????????????????????????????6′?????172.0
7?????36.4????????????????????????????????????2′-O-β-D-galactopyranosyl??moiety
8?????41.1????????????????????????????????????1???????104.9?????????5.32(1H，d，J＝7.5Hz)
9?????47.2????????????????????????????????????2???????73.5
10????37.0????????????????????????????????????3???????75.2
11????24.0????????????????????????????????????4???????69.8
12????125.5??????5.48(1H，brs)????????????????5???????76.7
13????143.7???????????????????????????????????6???????61.9
14????47.8????????????????????????????????????3′-O-α-L-arabinofuranosyl?moiety
15????67.6????????????????????????????????????1???????111.2????????6.03(1H，brs)
16????73.4????????????????????????????????????2???????83.6
17????48.4????????????????????????????????????3???????77.7
18????41.5????????????????????????????????????4???????85.5
19????47.0????????????????????????????????????5???????62.4
20????36.8????????????????????????????????????Angeloyl?moiety
21????78.6???????6.70(1H，d，J＝10.2Hz)???????1???????167.8
22????73.6???????6.32(1H，d，J＝10.2Hz)???????2???????129.0
23????28.0???????1.26(3H，s)??????????????????3???????137.4????????5.96(1H，q，J＝7.0Hz)
24????16.8???????1.16(3H，s)??????????????????4???????15.9?????????2.09(3H，dq，J＝7.0Hz)
25????15.8???????0.81(3H，s)??????????????????5???????21.0?????????2.00(3H，m)
26????17.6???????0.98(3H，s)??????????????????1???????168.2
27????21.3???????1.84(3H，s)??????????????????2???????129.2
28????63.2???????3.73，3.50(1H，d，J＝10.2Hz)?3???????136.6????????5.76(1H，q，J＝6.6Hz)
29????29.6???????1.09(3H，s)??????????????????4???????15.7?????????1.93(3H，dq，J＝6.6Hz)
In sum, the triterpene saponin componds that is found to be of new compound has increased a newcomer, thereby the utility value of depleted shinyleaf yellowhorn fruit shell and carpopodium is improved greatly, is expected to develop in field of medicaments from now on the new drug of treatment disease of brain and tumour.
Claims (9)
1. compound that from shinyleaf yellowhorn shell and handle, extracts, it is characterized in that: this compound is named and is Xanthoceraside, and its chemical structural formula is as follows:
2. the method for a compound that from shinyleaf yellowhorn shell and handle, extracts, it is characterized in that: shinyleaf yellowhorn fruit shell and/or carpopodium are pulverized, use the solvent lixiviate, filter, reclaim solvent and get concentrated solution, concentrated solution is crossed macroporous resin, use solvent elution, and the recovery solvent gets enriched material, evaporate to dryness, obtain brown solid, i.e. total saponins; With the total saponins water dissolution, use n-butanol extraction, the dry brown powder that gets through silica gel column chromatography, is carried out gradient elution with chloroform/methanol=100: 35～60, reclaims elutriant, and is refining, obtains white needle, is purpose compound Xanthoceraside.
3. according to the method for the described compound that extracts from shinyleaf yellowhorn shell and handle of claim 2, it is characterized in that: described solvent is water, methyl alcohol, ethanol, propyl alcohol, butanols and/or acetone.
4. according to the method for the described compound that extracts from shinyleaf yellowhorn shell and handle of claim 2, it is characterized in that: the concentration expressed in percentage by volume of described solvent methanol, ethanol, propyl alcohol, butanols or acetone is 35%～85%.
5. according to the method for the described compound that from shinyleaf yellowhorn shell and handle, extracts of claim 2, it is characterized in that: in the described solvent leaching process, adopt at interval and stir, promptly every 10～20 minutes, stirred 1～5 minute, extraction temperature is 60～100 ℃, and extraction time is 1～3 hour.
6. an application of compound of extracting from shinyleaf yellowhorn shell and handle is characterized in that: be used to prepare the medicine for the treatment of disease of brain.
7. an application of compound of extracting from shinyleaf yellowhorn shell and handle is characterized in that: the functional health care food that is used to prepare prevention, treatment disease of brain.
8. an application of compound of extracting from shinyleaf yellowhorn shell and handle is characterized in that: be used to prepare the medicine for the treatment of tumour.
9. an application of compound of extracting from shinyleaf yellowhorn shell and handle is characterized in that: the functional health care food that is used to prepare prevention, treatment tumour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100591402A CN1281616C (en) | 2004-07-07 | 2004-08-13 | Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410020921.0 | 2004-07-07 | ||
| CN200410020921 | 2004-07-07 | ||
| CNB2004100591402A CN1281616C (en) | 2004-07-07 | 2004-08-13 | Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1626545A true CN1626545A (en) | 2005-06-15 |
| CN1281616C CN1281616C (en) | 2006-10-25 |
Family
ID=34796383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100591402A Expired - Fee Related CN1281616C (en) | 2004-07-07 | 2004-08-13 | Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1281616C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007079695A1 (en) * | 2006-01-12 | 2007-07-19 | Liu Shujun | An extract of xanthoceras sorbifolia bunge and extraction and uses thereof |
| CN102018718A (en) * | 2010-12-06 | 2011-04-20 | 杨柏珍 | Application of Xanthoceraside compound |
| CN101139369B (en) * | 2007-09-10 | 2011-08-17 | 辽宁中医药大学 | Method for preparing Xanthoceras sorbifolia husk total saponin extractive |
| CN102180940A (en) * | 2011-04-02 | 2011-09-14 | 沈阳药科大学 | Preparation method of compound santhoceraside |
| CN102783654A (en) * | 2012-09-04 | 2012-11-21 | 山东理工大学 | Application of bunkanka saponin extract in weight losing and fat lowering fields |
| CN102813214A (en) * | 2012-09-04 | 2012-12-12 | 山东理工大学 | Application of xanthoceras sorbifolia saponin in field of reducing lipid and losing weight and preparation method of xanthoceras sorbifolia saponin |
| CN102823873A (en) * | 2012-09-04 | 2012-12-19 | 山东理工大学 | Application of xanthoceras sorbifolia flavone to field of skin whitening and preparation method of xanthoceras sorbifolia flavone |
| CN103509077A (en) * | 2012-06-15 | 2014-01-15 | 沈阳药科大学 | Triterpene saponin compound, its preparation method and applications |
| CN107137501A (en) * | 2017-05-27 | 2017-09-08 | 山西双林富农林开发有限公司 | It is a kind of to treat tinea pedis, the Chinese medicine composition of foot odour, preparation and preparation method thereof |
-
2004
- 2004-08-13 CN CNB2004100591402A patent/CN1281616C/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007079695A1 (en) * | 2006-01-12 | 2007-07-19 | Liu Shujun | An extract of xanthoceras sorbifolia bunge and extraction and uses thereof |
| CN101139369B (en) * | 2007-09-10 | 2011-08-17 | 辽宁中医药大学 | Method for preparing Xanthoceras sorbifolia husk total saponin extractive |
| CN102018718A (en) * | 2010-12-06 | 2011-04-20 | 杨柏珍 | Application of Xanthoceraside compound |
| CN102180940A (en) * | 2011-04-02 | 2011-09-14 | 沈阳药科大学 | Preparation method of compound santhoceraside |
| CN103509077A (en) * | 2012-06-15 | 2014-01-15 | 沈阳药科大学 | Triterpene saponin compound, its preparation method and applications |
| CN103509077B (en) * | 2012-06-15 | 2015-08-05 | 沈阳药科大学 | Triterpene saponin componds and its production and use |
| CN102783654A (en) * | 2012-09-04 | 2012-11-21 | 山东理工大学 | Application of bunkanka saponin extract in weight losing and fat lowering fields |
| CN102813214A (en) * | 2012-09-04 | 2012-12-12 | 山东理工大学 | Application of xanthoceras sorbifolia saponin in field of reducing lipid and losing weight and preparation method of xanthoceras sorbifolia saponin |
| CN102823873A (en) * | 2012-09-04 | 2012-12-19 | 山东理工大学 | Application of xanthoceras sorbifolia flavone to field of skin whitening and preparation method of xanthoceras sorbifolia flavone |
| CN107137501A (en) * | 2017-05-27 | 2017-09-08 | 山西双林富农林开发有限公司 | It is a kind of to treat tinea pedis, the Chinese medicine composition of foot odour, preparation and preparation method thereof |
| CN107137501B (en) * | 2017-05-27 | 2020-12-08 | 山西双林富农林开发有限公司 | Traditional Chinese medicine composition and preparation for treating beriberi and foot odor and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1281616C (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10160780B2 (en) | Compound extracted from husk and fruit stem of Xanthoceras sobifolia and its extracting method and use thereof | |
| CN1891240A (en) | Chinese medicine composition containing multi glossy ganoderma active constituents and its preparing method | |
| CN104341430A (en) | 3-phenylcoumarin robustic acid as well as extraction method and application thereof | |
| CN103800390A (en) | Health-care product with immunity-reinforcing and liver-protecting functions, preparation method and application thereof | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN1281616C (en) | Compound extracted from xanthoceras sorbifolia shells and stems, extraction method and application | |
| CN1724529A (en) | High purity cnidicin and preparation method thereof and be the pharmaceutical composition of activeconstituents with this compound | |
| CN103360452B (en) | The Synthesis and applications of Muskmelon Base tetracyclic triterpene cucurbitane compound | |
| CN102875615B (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN1303098C (en) | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine | |
| CN102477041A (en) | Preparation method of cepharanthine hydrochloride | |
| CN101085804A (en) | Method for preparing lonicera macranthoides hypo-saponin B and application of the same in curing liver cancer, breast carcinoma and cervical cancer | |
| CN1323793A (en) | Schizonepeta lactone and its extraction process and use | |
| CN1709903A (en) | Saponin compound and use of its glucoside in preparing medicine for treating neure injure | |
| CN100350902C (en) | Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan | |
| CN100341888C (en) | Anticancer new compound of Xiacaogan I, preparation method, and application in pharmacy | |
| CN103275139B (en) | 16 carbon diacetyl one double bond lactone type sophorolipid and application thereof | |
| CN103275138B (en) | 16 carbon diacetyls are without double bond lactone type sophorolipid and application thereof | |
| CN1582970A (en) | Extraction of effective portion of gryllotalpidae for anti-cancers and its preparation | |
| CN1733093A (en) | Process for preparing total saponin of anemone rhizome | |
| CN1850837A (en) | 9-(1,3-benzo dioxolyl-5_)-4-(beta-D-glucopyranosyloxy)-6,7-dimethoxy naphthale [2,3-C] furna-1(3II] ketone, and its preparing method and medicinal composition containing same | |
| CN1417218A (en) | Kaempferol derivative and its medicinal use | |
| CN1763069A (en) | Gen-seng saponin Rg2 preparation method, its pharmaceutical composition and uses in pharmacy | |
| CN1733748A (en) | Cyclohexenone analog bicyclo (condensed ring) compound and preparation method thereof and purposes | |
| CN1680290A (en) | Oximated ginger phenol and its synthesis and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CI03 | Correction of invention patent |
Correction item: Abstract of the description Correct: Reprint the correct prospectus summary False: Manual, abstract, publication, printing error Number: 43 Page: The title page Volume: 22 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ABSTRACT OF DESCRIPTION; FROM: ABSTRACT OF DESCRIPTION ERROR OF PRINT TO: REPUBLISH THE CORRECT ABSTRACT OF DESCRIPTION |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061025 Termination date: 20210813 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |